Wasatch Advisors Inc C4 Therapeutics, Inc. Transaction History
Wasatch Advisors Inc
- $19 Billion
- Q1 2024
A detailed history of Wasatch Advisors Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 4,328,479 shares of CCCC stock, worth $20 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
4,328,479
Previous 7,138,949
39.37%
Holding current value
$20 Million
Previous $40.3 Million
12.33%
% of portfolio
0.19%
Previous 0.22%
Shares
13 transactions
Others Institutions Holding CCCC
# of Institutions
111Shares Held
49.4MCall Options Held
455KPut Options Held
429K-
State Street Corp Boston, MA7.15MShares$33 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$15.8 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$13.5 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.46MShares$11.4 Million1.64% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.44MShares$11.3 Million0.04% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $226M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...